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Abstract
Background: Streptococcus mutans produces bacteriocins named mutacins. Studies of mutacins
have always been hampered by the difficulties in obtaining active liquid preparations of these
substances. Some of them were found to be lantibiotics, defined as bacterial ribosomally
synthesised lanthionine-containing peptides with antimicrobial activity. The goal of this study was
to produce and characterize a new mutacin from S. mutans strain 29B, as it shows a promising
activity spectrum against current human pathogens.
Results: Mutacin H-29B, produced by S. mutans strain 29B, was purified by successive hydrophobic
chromatography from a liquid preparation consisting of cheese whey permeate (6% w/v)
supplemented with yeast extract (2%) and CaCO3 (1%). Edman degradation revealed 24 amino
acids identical to those of mutacin II (also known as J-T8). The molecular mass of the purified
peptide was evaluated at 3246.08 ± 0.1 Da by MALDI-TOF MS.
Conclusion: A simple procedure for production and purification of mutacins along with its
characterization is presented. Our results show that the amino acid sequence of mutacin H-29B is
identical to the already known mutacin II (J-T8) over the first 24 residues. S. mutans strains of widely
different origins may thus produce very similar bacteriocins.
Background
Bacteriocins are ribosomally synthesised proteinaceous
bactericidal substances produced by bacteria [1].
Mutacins are bacteriocins produced by Streptococcus
mutans [2] that are active against Gram-positive and some
Gram-negative bacteria [3,4]. To date, four types of
mutacin have been described: the mono- or di-peptide
lantibiotic and the mono- or di-peptide non-lantibiotic
mutacin [5-8]. Lantibiotics contain unusual amino acids
such as Lan, BM-Lan and dehydrated amino acid residues
[9]. Posttranslational modification of the prepeptide
occurs through amino acid dehydration, formation of
thioether bridges and cleavage of the leader peptide dur-
ing transport outside of the cell [9].
We previously classified mutacin-producing strains into
24 groups (designated A to X) and 7 clusters according to
their activity spectra against bacterial pathogens and their
immunity towards other mutacins [10,4]. The strain 29B
producing mutacin H-29B was found to be closely related
in its activity spectrum with strain T8 which produces
mutacin II (also known as J-T8) [4]. The DNA probe
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T8) also hybridised with the DNA of strain 29B [11]. We
present here a simple procedure for production and puri-
fication of mutacin H-29B, along with its partial charac-
terization. The results show that the amino acid sequence
of mutacin H-29B is identical to that of mutacin II (J-T8)
over the first 24 residues. S. mutans strains of widely dif-
ferent origins may thus produce similar bacteriocins.
Results and discussion
Thermostability and pH stability
The activity of crude preparations of mutacin H-29B, cal-
culated at 6400 AU/ml (Table 1) at pH 4, was not reduced
in boiling water (100°C) after 1 h or after autoclaving
(121°C, 15 min), but lost 20% of its activity after 2 h at
100°C. All mutacin activity was retained at pH 2–4 after
24 h, but was reduced to 80% at pH 5–7, to 60% at pH 8–
9, and to 30% at pH 9–12. These results are in agreement
with previously published results obtained on the activity
of the mutacin-producing strain S. mutans 29B [10].
Purification and characterization of the mutacin H-29B
Purification of mutacin H-29B was achieved by means of
three hydrophobic chromatography steps (Table 1). The
final specific activity of the purified mutacin H-29B was
6.4 × 106 AU/mg. As for mutacin II (J-T8) [12,13], the
amino acid sequence of the purified mutacin H-29B was
blocked at position 9 without alkaline ethanethiol treat-
ment, indicating the presence of modified residues and
the lantibiotic nature of mutacin H-29B. This N-terminal
sequence was found to be identical to mutacin II (J-T8)
[12]. Balakrishnan et al. [14] also reported that mutacin M
19 presents the same N-terminal amino acid sequence.
The absence of methionine at the N-terminus suggests
that mutacin H-29B may be processed from a precursor
form, as reported for lantibiotics in general [9].
Edman degradation performed after alkaline ethanethiol
derivatization [15] revealed a total of 24 amino acids. The
complete sequence of mutacin H-29B confirms its iden-
tity with the mutacin II (J-T8). Modified amino acids were
obtained in positions 10, 12, 15, and 19. A BMSEC signal
seen as a doublet signal in cycle 10 indicates the presence
of an Abu or a dhB [15]. A SEC signal was observed in
positions 12, 15, and 19 during sequencing, which indi-
cate the presence of a dhA residue [15]. In each case, the
SEC signal was not accompanied by a DSER signal. At this
stage, we can not tell if the dhA or Abu residues are impli-
cated or not in the formation of thioether bridges. A
deamidation was also observed for the Asn and Gln in
positions 1, 5 and 18, which can result from the treatment
with alkaline ethanethiol. A Phe residue was observed as
a minor amino acid in position 25, probably resulting
from the carryover effect of the sequencing procedure.
Comparison of the mutacin H-29B sequence with known
bacteriocins revealed the high levels of homology to
group AII lantibiotics (Figure 1). However, the TCCS or
TCC motif present at the C-terminus of other AII lantibi-
otics was not detected by Edman degradation for mutacin
H-29B. The DNA sequence of the gene coding for mutacin
H-29B will confirm whether the TCC motif is also present
at the C-terminus of mutacin H-29B.
The molecular mass of mutacin H-29B determined by
MALDI-TOF MS (3246.08 ± 0.1 Da) is closely related to
the one estimated for mutacin II (J-T8) (3244.64 ± 1.15
Da) [13,16]. This strongly suggested that these two
mutacins are identical, including the three terminal
amino acids. Thus, the experimentally-demonstrated
thioether bridge pattern of mutacin II (J-T8) [16] can be
proposed for mutacin H-29B. These would consist of one
BM-Lan bridge between the residues in positions 10 (Thr)
and 15 (Cys), one Lan bridge between residues 12 (Ser)
and 26 (Cys) as well as a second Lan bridge between resi-
dues 19 (Ser) and 27 (Cys).
Different strains can produce the same mutacin: S. mutans
strains T8, isolated in Australia; UA96, isolated in Ala-
bama, USA; and 29B, isolated in Quebec, Canada [10,17],
produce mutacin II (J-T8) ([12,14], this paper); S. mutans
strains CH43 and UA140 produce mutacin I [7,18]; and S.
mutans JH 1140, isolated in Florida USA [19], and UA787,
isolated in Alabama, USA [20], produce the same
mutacin, that only differs from mutacin B-Ny266 by only
two amino acids [5].
Genes coding for mutacin biosynthesis have all been
located on the chromosome so far [7,8,18-22]. The
mutacin II (J-T8) gene cluster has been identified and suc-
Table 1: Purification of mutacin H-29B by hydrophobic chromatography.




Yield (%) Purification (fold)
Culture supernatant 1250 6400 10000 8000 800 100 1
XAD-7 Amberlite 300 6400 97.5 1920 20000 24 25
Sep-Pak C18 95 12800 1.9 1216 6.4 × 105 15.2 800
C18 RP-HPLC 1 6.4 × 105 0.1 640 6.4 × 106 8 8000Page 2 of 5
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mation [22]. Evolution of the mutacin-lantibiotics from a
common ancestor and its propagation via mobile genetic
elements is suggested by further observations. A silent
transposase gene was reported in the upstream region of
the genes coding for mutacin II (J-T8) production [22].
Yonezawa and Kuramitsu (2005) [8] also observed direct
repeats sequences flanking the Smb locus with similarity
to those of transposase genes directly downstream of the
locus. Sequences flanking the Smb locus were found adja-
cent in the UA159 S. mutans genome (GenBank Accession
No AE014133). Mutacin-lantibiotic coding genes could
perhaps be transferred via mobile genetic elements.
Conclusion
Mutacin (H-29B) was isolated from an active liquid cul-
ture of S. mutans strain isolated in Quebec (29B) and
proved to be identical to a previously characterized
mutacin II (alias J-T8). Mutacin-lantibiotic production by
S. mutans seems to be widespread despite the fact that the
reference genome strain for S. mutans (UA159) does not
seem to produce any of the mutacin lantibiotics character-
ized to date.
Methods
Bacterial strains and media
Streptococcus mutans 29B was previously described in Par-
rot et al. [17] and Micrococcus luteus ATCC 272 was from
the American Type Culture Collection (Manassas, VA,
USA). They were routinely grown aerobically at 37°C in
TSB (Difco laboratories, Detroit, MI, USA) supplemented
with 0.3% of Yeast Extract (Becton Dickinson & Co.,
Cockeysville, MD) (TSBYE) or on TSA (Difco) plates
enriched with 0.3% yeast extract (TSAYE).
Mutacin production
An overnight preculture in TSBYE was used to inoculate
(1%) 2 L of medium consisting of cheese whey permeate
6% (w/v) (kind gift from Agropur agroalimentary Coop,
Granby, QC, Canada) supplemented with 1% CaCO3
(Anachemia, Montreal, QC, Canada) and 2% yeast extract
(Institut Rosell Montreal, QC, Canada) (SWP). The cul-
ture was incubated 48 h at 37°C under aerobic conditions
[23].
Determination of inhibitory activity
Mutacin activity was determined as describe previously
[5] with the following modification: 2-fold dilutions were
prepared in acidified (pH 2) peptone water (0.5%) [23].
The specific activity of each preparation was expressed in
AU/mg protein. Protein concentration was determined
using the BioRad DC protein assay (BioRad, Mississauga,
ON, Canada).
Thermostability and pH stability
Crude mutacin (supernatant of SWP medium) was sub-
mitted to different pH conditions (pH 2 to pH 11)
adjusted with 4 N HC1 or 4 N NaOH. After 2 h and 24 h
at room temperature, residual mutacin activity was
assayed by the spot test described above. Non-inoculated
sterile SWP medium adjusted in the same conditions of
the tested sample was used as negative control. Ther-
mostability was assayed by determining the residual activ-
ity of crude mutacin samples adjusted at pH 4 and placed
in boiling water for up to 120 min and after autoclaving.
Mutacin H-29B extraction and purification
After 48 h of incubation at 37°C, the pH of the culture was
adjusted to 2.0 with 4 N HC1 and incubated for 2 h at
room temperature to desorb the mutacin [23]. The culture
was then centrifuged at 10,000 × g for 10 min and heated
at 70°C for 20 min to destroy the remaining cells and
enzyme activity. The purification steps were essentially
those previously used for the purification of mutacin B-
Ny266 [5] with the following modification: concentration
was carried out by adsorption to XAD-7 Amberlite (Sigma
Chemical CO., St Louis, MO, USA). Hydrophobic chro-
matography on Sep-Pak® Vac 35 cc (10 g) t-C18 Cartridges
(Waters Corporation, Milford, MA, USA) was performed
with the pooled active fractions diluted to 35% in MeOH
in 10 mM HCl. Active fractions were recovered with an
elution gradient of 50%–60% MeOH in 10 mM HC1. The
final purification step was carried out by reverse phase
chromatography (RP)-HPLC (Beckman Gold Model,
Coulter Canada Inc., Missisauga, ON, Canada) using an
analytical C18 column (Luna 5 µ C18(2), 250 × 4.6 mm, 4
× 3.0 mm, Phenomenex, Torrance, CA, USA). Elution was
carried out with 5% acetonitrile in 0.1% TFA and 60%
acetonitrile in 0.1% TFA and recorded at 214 nm.
Several re-injections of the same sample were made until
a unique peak was obtained. Active fractions were dried in
a Speed-Vac® concentrator (Model SC110A, Savant Instru-
ment Inc. Farmingdale, NY) and kept at -20°C for further
analyses.
Molecular mass determination
Molecular mass was determined for the purified HPLC
fraction by MALDI-TOF MS on a Voyager DE-PRO
(Applied Biosystems, Foster City, CA, USA) at the Peptide
Synthesis & Protein Sequencing Core facility of Eastern
Quebec, QC, Canada.
Sequence determination
Automated Edman degradation was performed on a pro-
tein sequencer (ABI Procise cLC, Applied Biosystems, Fos-
ter City, CA, USA) after alkaline ethanethiol derivatization
[15]. Pure mutacin B-Ny266 was used as control [5].
Homology searches were carried out with the NationalPage 3 of 5
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with Expect value = 0.01 and Search mode = multiple hits,
1 pass) [24].
Protein sequence accession number
The protein sequence data of mutacin H-29B appears in
the Swiss-Prot and TrEMBL knowledgebase under the
accession number P84110.
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